Benzinga··Vandana SinghNovartis Doubles Down on Allergies With $2B Excellergy Acquisition
Novartis acquires Excellergy for up to $2 billion to develop Exl-111, a next-generation anti-IgE allergy drug in Phase 1 trials, strengthening its immunology pipeline.
NVSacquisitionbiotech